Product Pathways - Apoptosis
DR3 Antibody #3254
|3254S||100 µl (10 western blots)||---||In Stock||---|
|3254||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
DR3 Antibody detects endogenous levels of human DR3. It is not expected to cross-react with other TNF receptor family members.
Source / Purification
DR3 Antibody is produced by immunizing rabbits with a synthetic peptide corresponding to residues within the intracellular domain of human DR3. Antibodies were purified by protein A and peptide affinity chromatography.
The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases.
DR3/WSL-1/Apo-3/TRAMP/LARD is a TNFR family member containing the characteristic extracellular cysteine-repeats, transmembrane region, and intracellular DD (3-7). DR3 is activated by its ligand Apo-3L/TWEAK to induce apoptosis and activation of NF-κB (8,9). Like TNF-R1, DR3 binds to the DD adaptor protein TRADD, which can then associate with other DD proteins like FADD and RIP as well as members of the TRAF family (3,4). Tissue expression of DR3 is very restricted, primarily seen on the surface of activated thymocytes and lymphocytes and plays an important role in thymocyte negative selection (3,4,10). Studies have also indicated an association with DR3 and rheumatoid arthritis (11,12).
- Nagata, S. (1997) Cell 88, 355-365.
- Thorburn, A. (2004) Cell. Signal. 16, 139-144.
- Chinnaiyan, A.M. et al. (1996) Science 274, 990-992.
- Kitson, J. et al. (1996) Nature 384, 372-375.
- Marsters, S.A. et al. (1996) Curr. Biol. 6, 1669-1676.
- Bodmer, J.L. et al. (1997) Immunity 6, 79-88.
- Screaton, G.R. et al. (1997) Proc. Natl. Acad. Sci. USA 94, 4615-4619.
- Marsters, S.A. et al. (1998) Curr. Biol. 8, 525-528.
- Kaptein, A. et al. (2000) FEBS Lett. 485, 135-141.
- Wang, E.C. et al. (2001) Mol. Cell Biol. 21, 3451-3461.
- Osawa, K. et al. (2004) Genes Immun. 5, 439-443.
- Borysenko, C.W. et al. (2005) Biochem. Biophys. Res. Commun. 328, 794-799.
- Jane, E.P. et al. (2011) Mol Cancer Ther 10, 198-208. Applications: Western Blotting.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 3696 DR5 Antibody
- 4273 FasL Antibody
- 2782 FADD Antibody (Human Specific)
- 3684 TRADD (7G8) Rabbit mAb
- 4926 RIP Antibody
- 4403 TWEAK Receptor/Fn14 Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.